ATA, Inc. (ATAI) Announces Proposed 14.286M IPO Between $13-$15/Sh

atai Life Sciences B.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares. All common shares to be sold in the proposed offering will be sold by atai. The underwriters of the offering will have a 30-day option to purchase up to an additional 2,142,900 common shares at the initial public offering price, less the underwriting discounts and commissions. The initial public offering price is expected to be between $13.00 and $15.00 per common share. atai has applied to list its common shares on the Nasdaq Global Market under the ticker symbol “ATAI.”

Credit Suisse, Citigroup, Cowen, and Berenberg are acting as book-running managers for the proposed offering. Cantor, RBC Capital Markets and Canaccord Genuity are also acting as book-running managers for the proposed offering.

The offering will be made only by means of a prospectus.

You May Also Be Interested In

• TMX Group closes C$1.1 billion private placement debenture offering
• American Savings Bank closes upsized IPO at $16 per share
• Clarivate sets pricing for tender offer on 2028 senior secured notes